REGENXBIO Inc. (RGNX)
RGNX moved a median of +0.35% 30 minutes after news, and +0.45% by the close. How RGNX actually reacts to news — the realized, point-in-time move the market made, measured across 696 labeled events over the last three years with zero look-ahead.
RGNX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.11% | 53% | 691 |
| 30-min | +0.35% | 54% | 693 |
| 60-min | +0.41% | 54% | 693 |
| to close | +0.45% | 57% | 691 |
| Middle 50% of RGNX reactions | -1.33% to +2.12% |
|---|---|
| Median reaction (30-min) | +0.35% |
| Measured reactions | 696 |
Half of all REGENXBIO Inc. news events land between -1.33% and +2.12% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How RGNX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 19 | -1.33% | 32% | -2.34% |
| Analyst downgrades | 14 | -1.49% | 36% | -1.08% |
| Coverage initiations | 13 | -0.57% | 31% | +0.43% |
| Rating reiterations | 94 | -0.35% | 43% | -0.49% |
| Price-target cuts | 13 | -0.41% | 31% | -0.67% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how RGNX ranks against every other measured name →
That’s how RGNX usually reacts — get an email when it moves on news →Email me when RGNX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to RGNX's baseline. Nothing else.
Recent RGNX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 | Press release | PR Newswire | -0.25% | -4.31% | |
| REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting | Press release | PR Newswire | -0.27% | -1.73% | |
| Form 8-K REGENXBIO Inc. For: Sep 23 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | -2.82% | |
| REGENXBIO to Participate in Upcoming Investor Conferences | Press release | PR Newswire | -2.57% | -2.12% | |
| Form 8-K REGENXBIO Inc. For: Aug 25 | SEC filing · Form 8-K | SEC EDGAR | -1.81% | +5.99% | |
| REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli | Press release | PR Newswire | +2.71% | +9.59% | |
| Form 8-K REGENXBIO Inc. For: Aug 24 | SEC filing · Form 8-K | SEC EDGAR | +2.71% | +9.59% | |
| REGENXBIO Announces Regulatory Update on RGX-121 for MPS II | Press release | PR Newswire | +1.02% | -2.83% | |
| Form 10-Q REGENXBIO Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.93% | +0.00% | |
| Form 8-K REGENXBIO Inc. For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +0.93% | +0.00% | |
| REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights | Press release | PR Newswire | +0.93% | +0.00% | |
| REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights | Press release | PR Newswire | -3.05% | +3.11% | |
| Form 8-K REGENXBIO Inc. For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +5.04% | +3.10% | |
| REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting | Press release | PR Newswire | +5.04% | +3.10% | |
| REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants | Press release | PR Newswire | -4.17% | +9.89% | |
| REGENXBIO Announces Proposed Public Offering of Common Stock | Press release | PR Newswire | -4.17% | +9.89% | |
| Form 8-K REGENXBIO Inc. For: Jun 23 | SEC filing · Form 8-K | SEC EDGAR | -0.09% | +7.54% | |
| REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone | Press release | PR Newswire | -0.09% | +7.54% | |
| REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 | Press release | PR Newswire | +4.32% | -2.06% | |
| REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II | Press release | PR Newswire | +0.70% | +6.46% | |
| Form 8-K REGENXBIO Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.78% | -0.59% | |
| REGENXBIO to Participate in Upcoming Investor Conferences | Press release | PR Newswire | -2.72% | -0.70% | |
| Form 10-Q REGENXBIO Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -12.13% | -22.71% | |
| Form 8-K REGENXBIO Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | -12.13% | -22.71% | |
| REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 | Press release | PR Newswire | -12.13% | -22.71% | |
| REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights | Press release | PR Newswire | -12.13% | -22.71% | |
| REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting | Press release | PR Newswire | +0.99% | +3.07% | |
| REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy | Press release | PR Newswire | -0.11% | +9.30% | |
| Form ARS REGENXBIO Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.18% | +0.75% | |
| Form DEF 14A REGENXBIO Inc. For: May 29 | SEC filing · Form DEF | SEC EDGAR | +1.18% | +0.75% | |
| Form DEFA14A REGENXBIO Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +1.18% | +0.75% | |
| REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX | Press release | PR Newswire | +1.18% | +0.75% | |
| Lifshitz Law PLLC Announces Investigations of REGENXBIO Inc. (NASDAQ: RGNX), Kyndryl Holdings, Inc. (NYSE: KD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) | Press release | ACCESS Newswire | -2.28% | -5.86% | |
| REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX | Press release | PR Newswire | +1.05% | +3.17% | |
| Form PRE 14A REGENXBIO Inc. For: May 29 | SEC filing · Form PRE | SEC EDGAR | +1.05% | +3.17% | |
| REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX | Press release | PR Newswire | -0.64% | +0.13% | |
| SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD | Press release | PR Newswire | +1.15% | +0.12% | |
| Form 8-K REGENXBIO Inc. For: Mar 18 | SEC filing · Form 8-K | SEC EDGAR | -1.14% | +0.00% | |
| STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP | Press release | PR Newswire | -1.59% | +2.20% | |
| STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST | Press release | PR Newswire | -1.18% | -2.47% | |
| REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | Press release | PR Newswire | -0.65% | +1.08% | |
| Form 10-K REGENXBIO Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.30% | +2.25% | |
| Form 8-K REGENXBIO Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | +3.69% | |
| REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | Press release | PR Newswire | -0.12% | +3.69% | |
| RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST | Press release | PR Newswire | — | +2.71% | |
| REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference | Press release | PR Newswire | -0.80% | +4.70% | |
| REGENXBIO to Participate in Upcoming Investor Conferences | Press release | PR Newswire | +4.02% | +6.08% | |
| REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX | Press release | PR Newswire | +0.06% | +4.87% | |
| REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights | Press release | PR Newswire | +4.46% | +5.57% | |
| REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX | Press release | PR Newswire | +2.19% | -3.17% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the RGNX section they belong to.
Where else RGNX is measured.
RGNX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| AB Corporate Bond ETF (EYEG) | 700 | 0.00% | 44% |
| STEMLINE THERAPEUTICS (STML) | 697 | +0.08% | 51% |
| ALDER BIOPHARMACEUTICALS INC (ALDR) | 693 | -0.21% | 45% |
| DIGIRAD (DRAD) | 692 | 0.00% | 39% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is REGENXBIO Inc.'s median reaction calculated?
Every labeled RGNX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 696 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 54% of RGNX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does RGNX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.